DM-1, sodium 4-[5-(4-hydroxy-3-methoxyphenyl)-3-oxo-penta-1,4-dienyl]-2-methoxy-phe nolate: a curcumin analog with a synergic effect in combination with paclitaxel in breast cancer treatment

Autor(es)

Faiao-Flores, Fernanda ^{[1, 2]} ; Quincoces Suarez, Jose Agustin ^[3] ; Pardi, Paulo Celso ^[4] ; Maria, Durvanei Augusto ^[2]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Fac Med, Sao Paulo - Brazil

^[2] Butantan Inst, Biochem & Biophys Lab, Sao Paulo - Brazil

^[3] Univ Bandeirante Sao Paulo, Organ Synth Lab, Sao Paulo - Brazil

^[4] Univ Bandeirante Sao Paulo, Lab Expt Pathol, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: TUMOR BIOLOGY; v. 33, n. 3, SI, p. 775-785, JUN 2012.
• Citações Web of Science: 13

Resumo

This paper describes a new method for the preparation of sodium 4-{[}5-(4-hydroxy-3-methoxyphenyl)-3-oxo-penta-1,4-dienyl]-2-methoxy-phe nolate, DM-1, and 3-oxo-penta-1,4-dienyl-bis (2-methoxy-phenolate), DM-2. The aim of this work was to evaluate the antitumor effects of DM-1 in adjuvant chemotherapy for breast cancer treatment. Mice bearing mammary adenocarcinomas (Ehrlich ascites tumors) were treated with paclitaxel alone, DM-1 alone, and paclitaxel + DM-1. Tumor samples were used to perform cytological analysis by the Papanicolaou method and apoptosis analysis by annexin V and phosphorylated caspase 3. The paclitaxel + DM-1 group had decreased tumor areas and tumor volumes, and the frequency of metastasis was significantly reduced. This caused a decrease in cachexia, which is usually caused by the tumor. Furthermore, treatment with paclitaxel + DM-1 and DM-1 alone increased the occurrence of apoptosis up to 40% in tumor cells, which is 35% more than in the group treated with paclitaxel alone. This cell death was mainly caused through phosphorylated caspase 3 (11% increase in paclitaxel + DM-1 compared to the paclitaxel group), as confirmed by reduced malignancy criteria in the ascitic fluid. DM-1 emerges as a potential treatment for breast cancer and may act as an adjuvant in chemotherapy, enhancing antitumor drug activity with reduced side effects. (AU)

• Processo FAPESP: 04/11351-0 - Sintese de heterociclos prenilados a partir de produtos naturais.
• Beneficiário: José Agustín Pablo Quincoces Suárez
• Linha de fomento: Auxílio à Pesquisa - Regular
• Processo FAPESP: 06/59450-1 - Avaliacao da atividade antitumoral do composto sintetico dm-1 em ani mais portadores de tumor de ehrlich.
• Beneficiário: Fernanda Faião Flores
• Linha de fomento: Bolsas no Brasil - Iniciação Científica